Over the last ten years, investigations have been performed at St Bartholomew's Hospital, the Royal Marsden Hospital and the Brompton Hospital into the relationship between fibrinolysis, circulating malignant cells and the prognosis of patients undergoing operation for colorectal cancer.
It has been suggested that circulating malignant cells which cannot implant could have a favourable prognostic significance and that the absence of such cells might represent a condition in which rapid implantation had occurred. Furthermore it has been suggested that circulating malignant cells were not associated with any worse outlook in cancer of the rectum cases at five years. Naturally occurring fibrinolytic activity is known to lead to the appearance of cells in the peripheral blood (Griffiths et al. 1973) .
The work leading to these conclusions has now been considerably extended by evaluating the tenyear follow up of patients. Circulating malignant cells were estimated at the time of operation by one of us (A J S) without clinical details or knowledge of the timing of blood samples and using techniques which have been outlined previously (Salsbury 1975 ). The patients were then followed patients studied was 42% (Table 1) . When excluding those who did not die from cancer, the corrected survival was 45 %. Of the 30 patients in whom no circulating malignant cells were demonstrated at the time of operation, only 27% were alive at ten years. The corrected survival, taking into account those patients who died of causes other than cancer was 30%. However, the tenyear survival of those 32 patients who had circulating malignant cells demonstrated at the time of surgery was 56 % and the corrected figure in this group was 58 % (Table 2 ) (P=5 %). Those patients who had circulating malignant cells at the end of operation (i.e. after ligation of the inferior mesenteric pedicle) had a 64 % survival compared with a 36 % corrected survival of those who had no circulating malignant cells at the time of operation (Table 3) It would, therefore, appear that circulating malignant cells give a more favourable prognosis and the marked differences in the clinical survival of our cases confirm our interpretation of this apparant paradox in respect of circulating malignant cells. This view is supported by experimental work which has shown that malignant cells which are kept circulating for some five hours in experimental situations appear to be non viable (Cliffton & Agostino 1962 , Dobrossy et al. 1968 , Romsdahl etal. 1961 ).
Because of our clinical results we have studied the effect of induced fibrinolysis in maintaining malignant cells circulating in the blood for, if our thesis is correct, it is important to keep malignant cells circulating.
In designing the protocol of our study, we decided to give a non-antigenic agent and therefore used urokinase. We also felt that it was important not actually to run the risk of causing malignant cells to be released from the primary tumour and consequently did not administer urokinase during operation until immediately after resection of the tumour. A dose of urokinase which led to demonstrable fibrinolysis during, and for a period of about five hours after, operation was assayed in 13 patients. There was no increased morbidity and fibrinolytic activity was measured by monitoring changes in fibrin degradation products (FDP) by the Thrombo-Welco test, and euglobulin lysis time (ELT) using the euglobulin fraction of plasma to lyse the patient's own clot (Dacie & Lewis 1975) The final protocol used for collecting samples is shown in Fig 1. The relationship of these to the beginning of operation, the height of the operation and the resection of the tumour can be seen. The dose of urokinase used was 10 000 Ptoug units (15 000 iu), two-hourly. This is very small when compared with a dose of 250 000 Ploug units (375 000 iu) given intravenously in cases of deep vein thrombosis. It is important to give urokinase at intervals of no more than two hours for, as shown by Tajima et al (1974) with intravenous infusion in dogs, blood activity falls to 20 % after two hours.
In 50 controls with no artificially induced fibrinolysis, malignant cells were not detected in showing distribution ofurokinase at two hours in liver andspleen the blood for longer than an hour after resection of the tumour and were never seen in the 24 hours after the conclusion of the operation. A similar pattern from a patient early in the series when we were giving urokinase at four-hourly intervals and not producing any significant fibrinolytic activity is seen in Fig 2. However, in Fig 3, it can be seen that when significant fibrinolytic activity was induced with injections of urokinase every two hours, circulating malignant cells could be found in the peripheral blood some five hours after resection of the tumour. We have found this in each of the 5 patients in whom we induced significant fibrinolytic activity immediately after resection of the tumour. The distribution of 99Tcm urokinase has been studied in one of us (H W). The urokinase was labelled according to the method described by Miller & Smith (1974) . It was found that urokinase was distributed in a pattern similar to that of a normal colloid scan, being taken up in the liver and spleen. This is to be expected as the molecular weight is 54 000. To eliminate the background activity of the urokinase due to its presence in the circulating blood, transferrin was labelled with "13Inm and its activity in the blood pool subtracted from that due to urokinase. The subtraction scan (Fig 4) shows the distribution of urokinase at two hours in the liver and spleen. The whole body count at this time is shown in Fig 5. Although much of the activity is now present in the bladder as urokinase is excreted in the urine, there is still a high concentration in the area of the liver and spleen, which are important regions for dissemination of colorectal carcinomas by blood entering the portal venous system. This work suggests that cells released at operation usually adhere to endothelium and become implanted, but if this is prevented they die. An increase in fibrinolytic activity resulting from the trauma of operation and supplemented by the administration of fibrinolytic enzymes leads to an increase in circulating malignant cells andy therefore improved patient survival. We feel that there are important implications in this work for adjuvant chemotherapy and immunotherapy.
